Bionure
Late-preclinical company focused at developing first-in-class sgk agonists for the treatment of rare ophthalmology diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD26—38m (Dealroom.co estimates May 2018.)
Company register number B67600346
Barcelona Catalonia (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
| N/A | N/A | Series A | |
€1.1m | Seed | ||
$4.7m | Series A | ||
N/A | Acquisition | ||
| Total Funding | CAD8.1m | ||
Related Content
Recent News about Bionure
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.